Cargando…

Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity

DX-8951f (exatecan mesylate), a new water-soluble derivative of camptothecin, is currently being evaluated in phase II clinical trials. Resistance may be acquired when treating cancer patients with DX-8951f. Therefore, we selected a subline of the human ovarian cancer cell line A2780 for resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Hattum, A H, Hoogsteen, I J, Schlüper, H M M, Maliepaard, M, Scheffer, G L, Scheper, R J, Kohlhagen, G, Pommier, Y, Pinedo, H M, Boven, E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364245/ https://www.ncbi.nlm.nih.gov/pubmed/12237778 http://dx.doi.org/10.1038/sj.bjc.6600508

Ejemplares similares

A New Water‐soluble Camptothecin Derivative, DX‐8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo
por: Mitsui, Ikuo, et al.
Publicado: (1995)

Characterization of a Human Small‐cell Lung Cancer Cell Line Resistant to a New Water‐soluble Camptothecin Derivative, DX‐8951f
por: Nomoto, Taisuke, et al.
Publicado: (1998)

Antitumor Effect of DX‐8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT‐11‐resistant Variants Cultured in vitro and Xenografted into Nude Mice
por: Takiguchi, Soichi, et al.
Publicado: (1997)

Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening.
por: Boven, E., et al.
Publicado: (1998)

Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models
por: Ogata, A, et al.
Publicado: (2008)

c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis
por: Arango, D, et al.
Publicado: (2003)

KPT-330 has antitumour activity against non-small cell lung cancer
por: Sun, H, et al.
Publicado: (2014)

In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles
por: Bradshaw, T D, et al.
Publicado: (2002)

Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity
por: Van heusden, J, et al.
Publicado: (2002)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo
por: Begleiter, A, et al.
Publicado: (2004)

Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells
por: Hamamura, R S, et al.
Publicado: (2007)

γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer
por: Mizugaki, H, et al.
Publicado: (2012)

An α-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen
por: Andersen, T T, et al.
Publicado: (2007)

Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts.
por: Kievit, E., et al.
Publicado: (1996)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo
por: Berthois, Y, et al.
Publicado: (2003)

A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours
por: Borriello, M, et al.
Publicado: (2011)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
por: Kususda, Y, et al.
Publicado: (2012)

Enhanced transplantability of human ovarian cancer lines in cyclophosphamide-pretreated nude mice.
por: Nauta, M. M., et al.
Publicado: (1986)

Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
por: Molthoff, C. F., et al.
Publicado: (1992)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
por: Legrier, M-E, et al.
Publicado: (2007)

Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs
por: Chen, Feng, et al.
Publicado: (2017)

Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo
por: Leong, C-O, et al.
Publicado: (2003)

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
por: Oflazoglu, E, et al.
Publicado: (2009)

Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo
por: Bannon, J H, et al.
Publicado: (2007)

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug
por: de Graaf, M, et al.
Publicado: (2002)

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
por: Caiazza, F, et al.
Publicado: (2015)

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
por: Pasquier, E, et al.
Publicado: (2013)

CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells
por: Fontijn, D, et al.
Publicado: (2006)

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
por: Martínez-Pérez, Carlos, et al.
Publicado: (2016)

Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo
por: Theys, J, et al.
Publicado: (2006)

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft
por: Petrangolini, G, et al.
Publicado: (2004)

Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells
por: Scheffer, G L, et al.
Publicado: (2002)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_g7n1tcao6vbhl9a8kdfq1glts0